LaVoie Group Logo
LaVoie Group Issues White Paper: Solving the Unique Problems of Orphan Drug Communications
October 18, 2012 10:40 ET | LaVoie Health Science
Cambridge, MA, Oct. 18, 2012 (GLOBE NEWSWIRE) -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), the acknowledged leader in life science, medtech and pharmaceutical communications, today...
Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
May 01, 2012 07:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review
April 30, 2012 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces EMA Acceptance for Review of Marketing Authorization Application for Lomitapide
March 20, 2012 07:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Fourth-Quarter and Full-Year 2011 Financial Results
March 06, 2012 07:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 6, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Submits Marketing Applications for Lomitapide in U.S. and EU
March 05, 2012 07:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 5, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals to Present at the Citi 2012 Global Healthcare Conference
February 22, 2012 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
February 09, 2012 08:00 ET | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
January 06, 2012 12:57 ET | Aegerion Pharmaceuticals, Inc.
Efficacy and Safety Profile Maintained Company to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion...
Siren Interactive Makes Inc. 5000 List for Second Consecutive Year
September 01, 2011 14:02 ET | Siren Interactive
Oak Park, IL, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Siren Interactive, a relationship marketing agency focused on rare disorder therapies, was recognized by Inc. magazine as ranking number 2,390 in the...